Companies / Harvard Bioscience Inc

Harvard Bioscience Inc

Nasdaq: HBIOCIK 1123494HOLLISTON, MAharvardbioscience.com ↗

Financials · FY2025

Revenue$86.55M
Net income$-56.70M
Total debt$36.68M
Cash$6.50M
Diluted EPS$-1.28
Shares outstanding4.6M

Ownership

4.6M shares outstanding · as of Aug 4, 2026
5.0%Insiders
Ownership
Insiders5.00%227,500
10%+ / strategic74.72%3,401,601
Institutions207.21%9,432,662
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 7

View all →
Insider% of sharesShares
Duke John DCEOChief Executive Officer · Director
3.95%180,000
Eade Katherine A.FormerDirector
1.29%58,669
Snider WilliamFormerDirector
1.07%48,556
Frost Mark TChief Financial Officer
1.04%47,500
Denelsky Stephen JFormerDirector
0.82%37,556
Benson Seth BenjaminFormerDirector
0.61%27,556
Gagnon Robert E.FormerDirector
0.61%27,556

Institutional holders 65

View all →
HolderValue% of shares
Weber Capital Management LLC /Adv$1.56M7.03%
Vanguard Group Inc$1.29M42.25%
Meros Investment Management, LP$814.4K26.75%
Corsair Capital Management, L.P.$607.8K2.74%
Two Sigma Advisers, LP$587.6K19.30%
Nano Cap New Millennium Growth Fund L P$572.2K2.58%
Two Sigma Investments, LP$555.8K2.51%
Renaissance Technologies LLC$493.9K2.23%
BlackRock, Inc.$380.3K1.36%
Geode Capital Management, LLC$289.9K1.31%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 16, 2026Snider William
Director
BuyCommon Stock$62.5K+13K
+113.86%
23,525
0.52% of shares
medium
Mar 17, 2026Denelsky Stephen J
Director
BuyCommon Stock$48.7K+10K
+90.91%
21,000
0.46% of shares
low
Mar 17, 2026Snider William
Director
BuyCommon Stock$41.1K+8K
+36.03%
32,000
0.70% of shares
low
Mar 16, 2026Duke John D
CEO
BuyCommon Stock$25.1K+5K
+5.00%
105,000
2.31% of shares
low
Mar 16, 2026Frost Mark T
Executive
BuyCommon Stock$25.0K+5K
+40.00%
17,500
0.38% of shares
low
Jun 9, 2026Eade Katherine A.
Director
GrantCommon Stock$0+17K
+39.31%
58,669
1.29% of shares
low
Jun 9, 2026Snider William
Director
GrantCommon Stock$0+17K
+51.74%
48,556
1.07% of shares
low
Jun 9, 2026Denelsky Stephen J
Director
GrantCommon Stock$0+17K
+78.84%
37,556
0.82% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Leviticus Partners LPPassive13G/A—3,401,601—
Leviticus Partners LPPassive13G/A—293,676—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
HBIOCommon StockEquity416906204BBG000C58Q08
HBIO——416906105—